Patents Assigned to Genentech
  • Publication number: 20160279260
    Abstract: This invention relates to peptidomimetic linkers and anti-body drug conjugates thereof, to pharmaceutical compositions containing them, and to their use in therapy for the prevention or treatment of cancer.
    Type: Application
    Filed: June 14, 2016
    Publication date: September 29, 2016
    Applicant: Genentech, Inc.
    Inventors: John Flygare, Janet Gunzner-Toste, Thomas Pillow, Brian Safina, Vishal Verma, Binqing Wei, Guiling Zhao, Leanna Staben
  • Publication number: 20160279142
    Abstract: Methods and compositions are provided for treating cancer in patients with a therapeutic combination comprising a therapeutically effective amounts of taselisib and palbociclib, or stereoisomers, geometric isomers, tautomers, or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: March 24, 2016
    Publication date: September 29, 2016
    Applicant: Genentech, Inc.
    Inventors: Lori Friedman, Michelle Nannini, Deepak Sampath, Jeffrey Wallin
  • Publication number: 20160279241
    Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents for the treatment of ovarian cancer.
    Type: Application
    Filed: June 16, 2016
    Publication date: September 29, 2016
    Applicant: Genentech, Inc.
    Inventors: Jakob Dupont, Cornelia Irl, Amreen Husain, Mika A. Sovak, Jing Yi, Hoa Nguyen
  • Patent number: 9453079
    Abstract: The invention provides antibodies to specific neural proteins and methods of using the same.
    Type: Grant
    Filed: May 30, 2014
    Date of Patent: September 27, 2016
    Assignee: Genentech, Inc.
    Inventors: Jasvinder Atwal, Yongmei Chen, Cecilia Pui Chi Chiu, Robert A. Lazarus, Weiru Wang, Ryan J. Watts, Yan Wu, Yingnan Zhang
  • Publication number: 20160274116
    Abstract: The invention provides methods for diagnosing prostate cancer. The invention also provides novel anti-STEAP-1 antibodies and uses thereof.
    Type: Application
    Filed: October 21, 2015
    Publication date: September 22, 2016
    Applicant: Genentech, Inc.
    Inventors: Siminder ATWAL, Jo-Anne HONGO, Mark LACKNER, Elizabeth PUNNOOSE, Bonnee RUBINFELD, Rajesh VIJ
  • Publication number: 20160272588
    Abstract: 2-Aminopyridine compounds of Formula I are provided, and various substituents including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for modulating USP7, and for treating cancer and immune disorders such as inflammation mediated by USP7. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: March 18, 2016
    Publication date: September 22, 2016
    Applicant: Genentech, Inc.
    Inventors: Robert Blake, Paola Di Lello, Jake Drummond, Christine Johanna Heideker, Lorna Kategaya, Till Maurer, Jeremy M. Murray, Chudi Ndubaku, Richard Pastor, Lionel Rouge, Vickie Tsui, Ingrid E. Wertz, Kebing Yu
  • Publication number: 20160272699
    Abstract: The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease.
    Type: Application
    Filed: October 28, 2015
    Publication date: September 22, 2016
    Applicants: GENENTECH, INC., AC IMMUNE S.A.
    Inventors: Andrea Pfeifer, Maria Pihlgren, Andreas Muhs, Ryan Watts
  • Publication number: 20160272631
    Abstract: Compounds of the formula I or II: or pharmaceutically acceptable salts thereof, wherein R1 is a group of formula (a), (b), (c); (d) or (e): and m, n, X, Y, R1, R2, R3, R4, Rb and Rc are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.
    Type: Application
    Filed: September 10, 2014
    Publication date: September 22, 2016
    Applicant: Genentech, Inc.
    Inventors: Benjamin Fauber, Alberto Gobbi
  • Publication number: 20160273044
    Abstract: Methods of identifying, diagnosing, and prognosing lupus, including certain subphenotypes of lupus, are provided, as well as methods of treating lupus, including certain subpopulations of patients. The methods provided are based on a set of alleles associated with systemic lupus erythematosus (SLE) risk loci including BLK, TNIP1, PRDM1, JAZF1, UHRF1BP1, IL10, IFIH1, CFB, CEC16A, IL12B and SH2B3 that contribute to SLE risk. Also provided are methods for identifying effective lupus therapeutic agents and predicting responsiveness to lupus therapeutic agents.
    Type: Application
    Filed: February 10, 2016
    Publication date: September 22, 2016
    Applicant: Genentech, Inc.
    Inventors: Timothy W. BEHRENS, Robert R. GRAHAM
  • Publication number: 20160264567
    Abstract: The invention is concerned with the compounds of formula I: and salts thereof and other compounds of formulas II-IX as disclosed herein. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formulas I-IX as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain or asthma.
    Type: Application
    Filed: February 12, 2016
    Publication date: September 15, 2016
    Applicant: Genentech, Inc.
    Inventors: Po-wai YUEN, Anthony ESTRADA, Huifen CHEN, Aleksandr KOLESNIKOV, Elisia VILLEMURE, Vishal VERMA, Lan WANG, Daniel SHORE, Steven DO, Matthew VOLGRAF, Baihua HU, Guosheng WU, Xingyu LIN, Aijun LU
  • Publication number: 20160265056
    Abstract: Biological markers that predict patient responsiveness to B-cell antagonists are provided. Also provided are methods of using such biological markers. In addition, methods for identifying patients suffering from an autoimmune disease, e.g., rheumatoid arthritis, who are not likely to respond to B-cell antagonists are provided, as are methods of treating such patients. Methods for selecting therapeutic agents to treat such patients are also provided.
    Type: Application
    Filed: February 9, 2016
    Publication date: September 15, 2016
    Applicant: Genentech, Inc.
    Inventors: Timothy W. BEHRENS, Kasia OWCZARCZYK, Michael J. TOWNSEND
  • Patent number: 9441035
    Abstract: Cell culture media are provided herein as are methods of using the media for cell culture and antibody production from cells. Compositions comprising antibodies and fragments thereof, produced by the methods herein are also provided.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: September 13, 2016
    Assignee: GENENTECH, INC.
    Inventors: Veronica Carvalhal, Natarajan Vijayasankaran, Lauren Brown, Thomas DiRocco, Nathan McKnight
  • Patent number: 9440976
    Abstract: The invention relates to 1,7-diazacarbazole compounds of Formula (I), (I-a) and (I-b) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chk1) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: September 13, 2016
    Assignee: GENENTECH, INC.
    Inventors: Hazel Joan Dyke, Lewis Gazzard, Karen Williams, Huifen Chen, Samuel Kintz, Joy Drobnick, Joseph P. Lyssikatos, Simon Goodacre, Calum Macleod, Charles Ellwood
  • Publication number: 20160257738
    Abstract: Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.
    Type: Application
    Filed: October 6, 2015
    Publication date: September 8, 2016
    Applicant: GENENTECH, INC.
    Inventors: Manuel Baca, James A. Wells, Leonard G. Presta, Henry B. Lowman, Yvonne Man-Yee Chen
  • Publication number: 20160257682
    Abstract: This invention relates to novel compounds which are inhibitors of T790M containing EGFR mutants, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of cancer.
    Type: Application
    Filed: May 12, 2016
    Publication date: September 8, 2016
    Applicant: Genentech, Inc.
    Inventors: Marian C. Bryan, Bryan Chan, Francois Diederich, Jennafer Dotson, Emily Hanan, Timothy Heffron, Michael Lainchbury
  • Patent number: 9434732
    Abstract: A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined herein, are useful as JAK kinase inhibitors. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of JAK kinase activity in a patient are disclosed.
    Type: Grant
    Filed: October 9, 2013
    Date of Patent: September 6, 2016
    Assignee: Genentech, Inc.
    Inventors: Bing-Yan Zhu, Michael Siu, Steven R. Magnuson, Richard Pastor, He Haiying, Xiao Yisong, Zheng Jifu, Xu Xing, Zhao Junping, Christopher Hurley, Jun Liang, Wendy Liu, Joseph P. Lyssikatos
  • Publication number: 20160251350
    Abstract: Disclosed are crystalline forms of (R)—N-(4-(3-aminopiperidin-1-yl)-5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)cyclopropanecarboxamide, and salts, solvates, and hydrates thereof, and pharmaceutical compositions, formulations and a process of manufacturing thereof.
    Type: Application
    Filed: February 26, 2016
    Publication date: September 1, 2016
    Applicants: Genentech, Inc., Array Biopharma Inc.
    Inventors: Jeffrey Stults, Christopher M. Lindemann, Keith L. Spencer, Weidong Liu, Joseph Lubach
  • Publication number: 20160250358
    Abstract: The present invention relates to deuterated and optionally detectably labeled compounds of formula (I) and formula (V): and salts thereof, wherein R1, R2, A, and X10-X19 have any of the values defined in the specification. Also included are pharmaceutical compositions comprising such compounds and salts, and methods of using such compounds and salts as imaging agents.
    Type: Application
    Filed: January 26, 2016
    Publication date: September 1, 2016
    Applicant: Genentech, Inc.
    Inventors: Jan Marik, Joseph P. Lyssikatos, Simon Williams
  • Publication number: 20160250287
    Abstract: Provided herein are combination therapies for the treatment of pathological conditions, such as cancer, using an antagonist of FGFR signaling.
    Type: Application
    Filed: March 6, 2014
    Publication date: September 1, 2016
    Applicant: Genentech, Inc.
    Inventors: Robert L. YAUCH, Xiaofen YE, Avi ASHKENAZI
  • Patent number: 9428548
    Abstract: The present invention provides methods for purifying a polypeptide comprising a CH2/CH3 region, comprising binding the polypeptide to Protein A and eluting with a pH gradient starting at a low pH.
    Type: Grant
    Filed: September 1, 2010
    Date of Patent: August 30, 2016
    Assignee: Genentech, Inc.
    Inventors: Arick Brown, Christopher J. Dowd, Asha Nandini Radhamohan